000163915 001__ 163915 000163915 005__ 20251113160752.0 000163915 0247_ $$2doi$$a10.1007/s12094-019-02145-4 000163915 0248_ $$2sideral$$a115288 000163915 037__ $$aART-2020-115288 000163915 041__ $$aeng 000163915 100__ $$aGavilá, J. 000163915 245__ $$aA retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study 000163915 260__ $$c2020 000163915 5203_ $$aPurpose: To evaluate the efficacy and safety of lapatinib (L) and trastuzumab (T) combination in HER2-positive metastatic breast cancer (MBC) patients previously treated with T and/or L. Materials and methods: We conducted a retrospective, post-authorized, multicenter study including patients with HER2-positive MBC or locally advanced breast cancer (ABC) treated with the combination of L–T. Concomitant endocrine therapy, as well as brain metastasis and/or prior exposure to L, were allowed. Results: One hundred and fifteen patients from 14 institutions were included. The median age was 59.8 years. The median number of prior T regimens in the advanced setting was 3 and 73 patients had received a prior L regimen. The clinical benefit rate (CBR) was 34.8% (95% CI 26.1–43.5). Among other efficacy endpoints, the overall response rate was 21.7%, and median progression-free survival (PFS) and overall survival were 3.9 and 21.6 months, respectively. Heavily pretreated and ≥ 3 metastatic organ patients showed lower CBR and PFS than patients with a low number of previous regimens and < 3 metastatic organs. Moreover, CBR did not significantly change in L-pretreated compared with L-naïve patients (31.5% versus 40.5% for L-pretreated versus L-naïve). Grade 3/4 adverse events were reported in 19 patients (16.5%). Conclusion: The combination of L–T is an effective and well-tolerated regimen in heavily pretreated patients and remains active among patients progressing on prior L-based therapy. Our study suggests that the L–T regimen is a safe and active chemotherapy-free option for MBC patients previously treated with T and/or L. 000163915 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/ 000163915 590__ $$a3.405$$b2020 000163915 591__ $$aONCOLOGY$$b159 / 241 = 0.66$$c2020$$dQ3$$eT2 000163915 592__ $$a0.902$$b2020 000163915 593__ $$aCancer Research$$c2020$$dQ2 000163915 593__ $$aOncology$$c2020$$dQ2 000163915 593__ $$aMedicine (miscellaneous)$$c2020$$dQ2 000163915 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion 000163915 700__ $$aDe La Haba, J. 000163915 700__ $$aBermejo, B. 000163915 700__ $$aRodríguez-Lescure, Á. 000163915 700__ $$0(orcid)0000-0002-9159-4988$$aAntón, A.$$uUniversidad de Zaragoza 000163915 700__ $$aCiruelos, E. 000163915 700__ $$aBrunet, J. 000163915 700__ $$aMuñoz-Couselo, E. 000163915 700__ $$aSantisteban, M. 000163915 700__ $$aRodríguez Sánchez, C.A. 000163915 700__ $$aSantaballa, A. 000163915 700__ $$aSánchez Rovira, P. 000163915 700__ $$aGarcía Sáenz, J. Á. 000163915 700__ $$aRuiz-Borrego, M. 000163915 700__ $$aGuerrero-Zotano, A.L. 000163915 700__ $$aHuerta, M. 000163915 700__ $$aCotes-Sanchís, A. 000163915 700__ $$aLao Romera, J. 000163915 700__ $$aAguirre, E. 000163915 700__ $$aCortés, J. 000163915 700__ $$aLlombart-Cussac, A. 000163915 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000163915 773__ $$g22 (2020), 420-428$$pClin. transl. oncol.$$tClinical and Translational Oncology$$x1699-048X 000163915 8564_ $$s1051735$$uhttps://zaguan.unizar.es/record/163915/files/texto_completo.pdf$$yPostprint 000163915 8564_ $$s2371554$$uhttps://zaguan.unizar.es/record/163915/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint 000163915 909CO $$ooai:zaguan.unizar.es:163915$$particulos$$pdriver 000163915 951__ $$a2025-11-13-14:57:46 000163915 980__ $$aARTICLE